Akihiro Ito1, Yoshihiro Yamamoto2, Yoshikazu Ishii3, Akihito Okazaki4, Yoshihisa Ishiura5, Yukio Kawagishi6, Yasuo Takiguchi7, Kazuma Kishi8, Yoshio Taguchi9, Takashi Shinzato10, Yasumi Okochi11, Ryuji Hayashi12, Yoshitaka Nakamori13, Yoshiko Kichikawa14, Kengo Murata15, Hiroaki Takeda16, Futoshi Higa17, Takayuki Miyara18, Keisuke Saito19, Takeo Ishikawa20, Tadashi Ishida21, Kazuhiro Tateda22. 1. Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, Japan. Electronic address: ai12306@kchnet.or.jp. 2. Department of Clinical Infectious Diseases, Toyama University Hospital, 2630 Sugitani, Toyama, Toyama 930-0194, Japan. Electronic address: yamamoto@med.u-toyama.ac.jp. 3. Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan. Electronic address: yishii@med.toho-u.ac.jp. 4. Department of Respiratory Medicine, Koseiren Takaoka Hospital, 5-10 Eirakumachi, Takaoka, Toyama 933-8555, Japan. Electronic address: akihitookazaki1017@gmail.com. 5. First Department of Internal Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8507, Japan. Electronic address: ishiuray@takii.kmu.ac.jp. 6. Department of Internal Medicine, Kurobe City Hospital, 1108-1 Mikkaichi, Kurobe, Toyama 938-8502, Japan. Electronic address: kawagishi-tym@umin.ac.jp. 7. Department of Respiratory Medicine, Chiba Aoba Municipal Hospital, 1273-2 Aoba-chou, Chuo-ku, Chiba, Chiba 260-0852, Japan. Electronic address: takiguchi@ninus.ocn.ne.jp. 8. Department of Respiratory Medicine, Toho University Omori Medical Center, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan. Electronic address: kazuma.kishi@med.toho-u.ac.jp. 9. Department of Respiratory Medicine, Tenri Hospital, 200 Mishima-cho, Tenri, Nara 632-8552, Japan. Electronic address: ytaguchi@tenriyorozu.jp. 10. Department of Infectious Diseases and Internal Medicine, Nakagami General Hospital, 610 Noborikawa, Okinawa, Okinawa 904-2195, Japan. Electronic address: takashinzato@nakagami.or.jp. 11. Department of Respiratory Medicine, Japan Community Health Care Organization, Tokyo Yamate Medical Center, 3-22-1 Hyakunin-cho, Shinjuku-ku, Tokyo 169-0073, Japan. Electronic address: okochi@mac.com. 12. Clinical Oncology, Toyama University Hospital, 2630 Sugitani, Toyama, Toyama 930-0194, Japan. Electronic address: hsayaka@med.u-toyama.ac.jp. 13. Division of Respiratory Medicine, Mishuku Hospital, 5-33-12 Kamimeguro, Meguro-ku, Tokyo 153-0051, Japan. Electronic address: nakamori@toranomon.or.jp. 14. Division of Respiratory Medicine, Mishuku Hospital, 5-33-12 Kamimeguro, Meguro-ku, Tokyo 153-0051, Japan. Electronic address: ykichi@mishuku.gr.jp. 15. Department of Respiratory Medicine, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-8524, Japan. Electronic address: kengo_murata@tmhp.jp. 16. Department of Respiratory Medicine, Yamagata Saisei Hospital, 79-1 Okimachi, Yamagata, Yamagata 990-8545, Japan. Electronic address: takeda@ameria.org. 17. Department of Internal Medicine, National Hospital Organization Okinawa Hospital, 3-20-14 Ganeko, Ginowan, Okinawa 901-2214, Japan. Electronic address: fhiga-ok@umin.ac.jp. 18. Department of Infection Prevention and Control, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan. Electronic address: miyarat@med.kobe-u.ac.jp. 19. Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishi-shinbashi, Minato-ku, Tokyo, Japan. Electronic address: ksaito.keisuke@gmail.com. 20. Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University Daisan Hospital, 4-11-1 Izumihoncho, Komae, Tokyo 201-8601, Japan. Electronic address: takeo-i@fa2.so-net.ne.jp. 21. Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama 710-8602, Japan. Electronic address: ishidat@kchnet.or.jp. 22. Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan. Electronic address: kazu@med.toho-u.ac.jp.
Abstract
OBJECTIVES: The aim of this study was to evaluate the diagnostic utility of a novel test kit that could theoretically detect all serogroups ofLegionella pneumophila for diagnosing Legionella pneumonia compared with existing kits. METHODS: This study was conducted in 16 hospitals in Japan from April 2016 to December 2018. Three urinary antigen test kits, including the novel kit (LAC-116), Binax NOWLegionella (Binax), and Q-line Kyokutou Legionella (Q-line), were used. In addition, culture and nucleic acid detection tests of sputum and serum antibody tests were performed where possible. The diagnostic accuracy and correlations of the novel kit with the two existing kits were analyzed. RESULTS: In total, 56 patients were diagnosed withLegionella pneumonia. The sensitivities of LAC-116, Binax, and Q-line were 79%, 84%, and 71%, respectively. The overall match rate was 96.8% between LAC-116 and Binax and 96.4% between LAC-116 and Q-line. One patient had L. pneumophila serogroup 2, and only LAC-116 showed a positive result, whereas Binax and Q-line did not. CONCLUSIONS: The novelLegionella urinary antigen test kit was useful for diagnosing Legionella pneumonia. In addition, it could detect Legionella pneumonia caused by non-L. pneumophila serogroup 1.
OBJECTIVES: The aim of this study was to evaluate the diagnostic utility of a novel test kit that could theoretically detect all serogroups ofLegionella pneumophila for diagnosing Legionella pneumonia compared with existing kits. METHODS: This study was conducted in 16 hospitals in Japan from April 2016 to December 2018. Three urinary antigen test kits, including the novel kit (LAC-116), Binax NOWLegionella (Binax), and Q-line Kyokutou Legionella (Q-line), were used. In addition, culture and nucleic acid detection tests of sputum and serum antibody tests were performed where possible. The diagnostic accuracy and correlations of the novel kit with the two existing kits were analyzed. RESULTS: In total, 56 patients were diagnosed withLegionella pneumonia. The sensitivities of LAC-116, Binax, and Q-line were 79%, 84%, and 71%, respectively. The overall match rate was 96.8% between LAC-116 and Binax and 96.4% between LAC-116 and Q-line. One patient had L. pneumophila serogroup 2, and only LAC-116 showed a positive result, whereas Binax and Q-line did not. CONCLUSIONS: The novelLegionella urinary antigen test kit was useful for diagnosing Legionella pneumonia. In addition, it could detect Legionella pneumonia caused by non-L. pneumophila serogroup 1.